Now that the door is open: an update on ischemic stroke pharmacotherapeutics for the neurointerventionalist.

Autor:	Fraser JF; Department of Neurological Surgery, University of Kentucky, Lexington, Kentucky, USA Jfr235@uky.edu.; Department of Neurology, University of Kentucky, Lexington, Kentucky, USA.; Department of Radiology, University of Kentucky, Lexington, Kentucky, USA., Pahwa S; Department of Neurological Surgery, University of Kentucky, Lexington, Kentucky, USA.; Department of Radiology, University of Kentucky, Lexington, Kentucky, USA., Maniskas M; Department of Neurology, The University of Texas Health Science Center at Houston John P and Katherine G McGovern Medical School, Houston, Texas, USA., Michas C; Department of Neurological Surgery, University of Kentucky, Lexington, Kentucky, USA., Martinez M; Department of Neurointerventional Radiology, Indiana University School of Medicine, Indianapolis, Indiana, USA., Pennypacker KR; Department of Neurology, University of Kentucky, Lexington, Kentucky, USA.; University of Kentucky, Lexington, Kentucky, USA., Dornbos D 3rd; Department of Neurological Surgery, University of Kentucky, Lexington, Kentucky, USA.
Jazyk:	angličtina
Zdroj:	Journal of neurointerventional surgery [J Neurointerv Surg] 2024 Mar 14; Vol. 16 (4), pp. 425-428. Date of Electronic Publication: 2024 Mar 14.
DOI:	10.1136/jnis-2022-019293
Abstrakt:	The last 10 years have seen a major shift in management of large vessel ischemic stroke with changes towards ever-expanding use of reperfusion therapies (intravenous thrombolysis and mechanical thrombectomy). These strategies 'open the door' to acute therapeutics for ischemic tissue, and we should investigate novel therapeutic approaches to enhance survival of recently reperfused brain. Key insights into new approaches have been provided through translational research models and preclinical paradigms, and through detailed research on ischemic mechanisms. Additional recent clinical trials offer exciting salvos into this new strategy of pairing reperfusion with neuroprotective therapy. This pairing strategy can be employed using drugs that have shown neuroprotective efficacy; neurointerventionalists can administer these during or immediately after reperfusion therapy. This represents a crucial moment when we emphasize reperfusion, and have the technological capability along with the clinical trial experience to lead the way in multiprong approaches to stroke treatment. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu